Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.

Authors:
Dr. Cheng-Jun Hu, PhD
Dr. Cheng-Jun Hu, PhD
University of Colorado
Associate Professor
Pulmonary hypertension
Aurora, CO | United States
Hui Zhang
Hui Zhang
College of Veterinary Medicine
Australia
Soni S Pullamsetti
Soni S Pullamsetti
University of Giessen Lung Center
Germany
Kurt R Stenmark
Kurt R Stenmark
University of Colorado Health Sciences Center
United States

J Physiol 2019 Feb 7;597(4):1103-1119. Epub 2018 Aug 7.

Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Chronic pulmonary hypertension (PH) is characterized by the accumulation of persistently activated cell types in the pulmonary vessel exhibiting aberrant expression of genes involved in apoptosis resistance, proliferation, inflammation and extracellular matrix (ECM) remodelling. Current therapies for PH, focusing on vasodilatation, do not normalize these activated phenotypes. Furthermore, current approaches to define additional therapeutic targets have focused on determining the initiating signals and their downstream effectors that are important in PH onset and development. Although these approaches have produced a large number of compelling PH treatment targets, many promising human drugs have failed in PH clinical trials. Herein, we propose that one contributing factor to these failures is that processes important in PH development may not be good treatment targets in the established phase of chronic PH. We hypothesize that this is due to alterations of chromatin structure in PH cells, resulting in functional differences between the same factor or pathway in normal or early PH cells versus cells in chronic PH. We propose that the high expression of genes involved in the persistently activated phenotype of PH vascular cells is perpetuated by an open chromatin structure and multiple transcription factors (TFs) via the recruitment of high levels of epigenetic regulators including the histone acetylases P300/CBP, histone acetylation readers including BRDs, the Mediator complex and the positive transcription elongation factor (Abstract figure). Thus, determining how gene expression is controlled by examining chromatin structure, TFs and epigenetic regulators associated with aberrantly expressed genes in pulmonary vascular cells in chronic PH, may uncover new PH therapeutic targets.

Download full-text PDF

Source
http://dx.doi.org/10.1113/JP275857DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375873PMC
February 2019
8 Reads
5.040 Impact Factor

Publication Analysis

Top Keywords

persistently activated
12
chromatin structure
12
cells chronic
8
genes involved
8
therapeutic targets
8
expression genes
8
pulmonary hypertension
8
epigenetic regulators
8
vascular cells
8
activated cell
8
treatment targets
8
cells
5
structure multiple
4
drugs failed
4
mediator complex
4
promising human
4
human drugs
4
clinical trials
4
contributing factor
4
including brds
4

References

(Supplied by CrossRef)

Similar Publications